These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 20627986

  • 21. Treatment of exudative age-related macular degeneration: many factors to consider.
    Olsen TW.
    Am J Ophthalmol; 2007 Aug; 144(2):281-3. PubMed ID: 17659955
    [No Abstract] [Full Text] [Related]

  • 22. The use of bevacizumab for the treatment of colorectal cancer.
    Beaumont I.
    Int J Palliat Nurs; 2010 Dec; 16(12):576. PubMed ID: 21240099
    [No Abstract] [Full Text] [Related]

  • 23. Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds.
    Torjesen I.
    BMJ; 2013 Jul 23; 347():f4678. PubMed ID: 23881948
    [No Abstract] [Full Text] [Related]

  • 24. Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.
    Silver J.
    JAMA; 2014 Jul 02; 312(1):23-4. PubMed ID: 24860863
    [No Abstract] [Full Text] [Related]

  • 25. What is the real cost of bevacizumab for patients with advanced bowel cancer?
    Dixon L.
    Int J Palliat Nurs; 2010 Dec 02; 16(12):577. PubMed ID: 21240100
    [No Abstract] [Full Text] [Related]

  • 26. Off-label prescribing in macular degeneration.
    McCartney M.
    BMJ; 2011 Oct 19; 343():d6778. PubMed ID: 22012651
    [No Abstract] [Full Text] [Related]

  • 27. [Bevacizumab or ranibizumab, or the tale of Robin Hood and King Richard Lion Heart].
    Monés J.
    Arch Soc Esp Oftalmol; 2007 Sep 19; 82(9):529-30. PubMed ID: 17846939
    [No Abstract] [Full Text] [Related]

  • 28. Identifying and eliminating the roadblocks to comparative-effectiveness research.
    Martin DF, Maguire MG, Fine SL.
    N Engl J Med; 2010 Jul 08; 363(2):105-7. PubMed ID: 20519677
    [No Abstract] [Full Text] [Related]

  • 29. Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?
    Ziemssen F, Grisanti S, Bartz-Schmidt KU, Spitzer MS.
    Drugs Aging; 2009 Jul 08; 26(4):295-320. PubMed ID: 19476398
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. An ethical view of the ranibizumab and bevacizumab controversy.
    Packer S, Jampol LM.
    Arch Ophthalmol; 2008 Feb 08; 126(2):286; author reply 286-7. PubMed ID: 18268234
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements.
    Shah AR, Del Priore LV.
    Br J Ophthalmol; 2009 Aug 08; 93(8):1027-32. PubMed ID: 19429594
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.